Molecular targeted therapies in metastatic melanoma
Authors:
Open Access
- 1 June 2013
- journal article
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. 6, 49-56
Abstract
The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. The discovery of BRAF mutations in melanoma led to the development of BRAF inhibitors for the treatment of advanced melanoma. However, growing concerns over drug resistance to molecular targeted therapies including BRAF inhibitors, have spurred efforts to elucidate additional molecular targets for the treatment of advanced melanoma. In this review, we discuss the known molecular aberrations in melanoma, current and novel targeted approaches in its treatment, and drug resistance patterns.Keywords
This publication has 74 references indexed in Scilit:
- Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)Journal of Translational Medicine, 2012
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic studyJournal of the American Academy of Dermatology, 2012
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- NRAS mutation status is an independent prognostic factor in metastatic melanomaCancer, 2011
- Malignant Melanoma in the 21st Century: The Emerging Molecular LandscapeMayo Clinic Proceedings, 2008
- Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMolecular Oncology, 2007
- In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP SignalingCancer Research, 2006
- Risk of Melanoma Arising in Large Congenital Melanocytic Nevi: A Systematic ReviewPlastic and Reconstructive Surgery, 2004
- Differences in in vitro invasive capacity induced by differences in Ki‐Ras protein mutationsThe Journal of Pathology, 2001